Lv741
5010 积分 2023-08-18 加入
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
14天前
已完结
Is there a future for Trop-2-targeted ADCs in urothelial carcinoma?
14天前
已完结
The Achilles heel of precision AKT-targeted therapies in advanced prostate cancer: therapeutic promise constrained by the test
14天前
已关闭
Long-term outcomes with adjuvant CDK4/6 inhibitors: who benefits most?
14天前
已关闭
Apocrine Intraductal Carcinoma With A Frankly Invasive Salivary Duct Carcinoma Component: A Case Report Showing Novel Genetic Alterations
1个月前
已完结
"PIK"ing the Right Patients for Adjuvant Aspirin Therapy for Colorectal Cancer
1个月前
已完结
The Expanding Landscape of Next-Generation EGFR Tyrosine Kinase Inhibitors: Have We Reached Capacity?
2个月前
已关闭
Priming for Cure: How Perioperative Immunotherapy Is Redrawing Surgical Boundaries
2个月前
已完结
Is Pleural Invasion Always Pleural Invasion?
2个月前
已完结
Immune Checkpoint Inhibitor Monotherapy for Patients With Pulmonary Sarcomatoid Carcinoma-The Optimal Therapeutic Strategy for This Rare Lung Cancer Subtype?
2个月前
已完结
皖公网安备34019202002308
